Safeguard Scientifics’ Jim Datin Discusses Biotech Investing Trends in 2010
Posted by | February 2, 2010
James A. Datin, EVP and Managing Director of Safeguard Scientifics‘ Life Sciences Group, was recently interviewed by FierceBiotech, a leading industry online publication, about biotech investment trends in 2010.
“Regenerative medicine is the next revolution in medicine,” says Datin. “It goes beyond just treatment with a drug to completely fixing an illness or condition. Regenerative medicine could totally change the way people receive treatment.”
Drug delivery technology that improves the effectiveness of already approved drugs will be a “no-brainer for investors,” he says. Safeguard’s life sciences Group targets growth-stage companies focused on molecular and point-of-care diagnostics, medical devices, regenerative medicine, and specialty pharmaceuticals.
The financial crisis of 2009 will lead to fewer large investment rounds, and will cause investors to focus more on lead products and potential commercialization opportunities, rather than “mass-market” drugs.
A stagnant IPO market also has had a far-reaching impact on the industry. Venture capital firms have had to finance their investments longer than originally planned, and this has enabled big pharma to ink deals at what VCs consider below-market valuations.
Check out more from Jim in the complete article.
